Use of guideline recommended follow-up care in cancer survivors - Routine or diagnostic indications?

被引:21
作者
Cooper, Gregory S.
Johnson, Christine Cole
Lamerato, Lois
Poisson, Laila M.
Schultz, Lonni
Simpkins, Jan
Wells, Karen
Yood, Marianne Ulcickas
Chase, Gary
Nathanson, S. David
Lafata, Jennifer Elston
机构
[1] Case Western Reserve Univ, Div Gastroenterol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA
[3] Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI USA
[4] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI USA
[5] Henry Ford Hlth Syst, Surg Oncol, Detroit, MI USA
[6] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA
[7] Yale Univ, Sch Med, New Haven, CT USA
[8] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Hlth Evaluat Sci, Hershey, PA 17033 USA
关键词
breast cancer; colorectal cancer; endometrial cancer; lung cancer; prostate cancer; cancer survivors; surveillance;
D O I
10.1097/01.mlr.0000215902.50543.77
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: After potentially curative cancer treatment, patients may receive procedures for routine monitoring for recurrence or for evaluation of symptoms or signs. Objective: We sought to characterize surveillance care guideline-recommended and other procedures performed in cancer survivors according to routine versus diagnostic indications. Methods: This was a retrospective cohort study of paper and electronic medical records between 1990 and 2000 from a large midwestem U.S. integrated health care delivery system of 500 patients who received curative treatment of breast, colorectal, endometrial, lung, or prostate cancer. Our measures were the indications for potential surveillance procedures as recommended by clinical practice guidelines or otherwise. Results: Among 14,670 procedures of interest received, 82.0% were performed for routine surveillance, whereas 10.6% were performed for diagnostic indications and 7.3% had indeterminate indications. Office visits most were often delivered for routine indications (91.6%), followed by guideline recommended tests for local recurrence (range 74.1-98.4%, depending on the specific test and cancer). In general, tests that were not recommended in established guidelines were for the purposes of detection of metastatic recurrence and were less often delivered for routine indications (overall frequency 59.2%, P < 0.0001 compared with recommended testing). Conclusion: Office visits and testing for local recurrence of cancer generally are performed for routine surveillance, regardless of recommendation by practice guidelines. Because procedures not recommended by practice guidelines were more often for diagnostic purposes, classification of patients as undergoing intensive surveillance may be misleading and may require record review to confirm.
引用
收藏
页码:590 / 594
页数:5
相关论文
共 25 条
[11]  
*NAT COMPR CANC NE, 2002, COL CANC PRACT GUID
[12]  
*NAT COMPR CANC NE, 2002, SMALL CELL LUNG CANC
[13]  
*NAT COMPR CANC NE, 2002, NON SMALL CELL LUNG
[14]  
*NAT COMPR CANC NE, 2002, BREAST CANC PRACT GU
[15]  
*NAT COMPR CANC NE, 2002, PROST CANC PRACT GUI
[16]  
*NAT COMPR CANC NE, 2001, END CANC PRACT GUID
[17]  
Nattinger AB, 2002, MED CARE, V40, P69
[18]   Follow-up care of breast cancer survivors [J].
Partridge, AH ;
Winer, EP ;
Burstein, HJ .
SEMINARS IN ONCOLOGY, 2003, 30 (06) :817-825
[19]  
REDDOCH JM, 1995, GYNECOL ONCOL, V59, P221
[20]   American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines [J].
Smith, TJ ;
Davidson, NE ;
Schapira, DV ;
Grunfeld, E ;
Muss, HB ;
Vogel, VG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :1080-1082